ValuEngine downgraded shares of Asterias Biotherapeutics Inc (NYSEMKT:AST) from a hold rating to a sell rating in a research report sent to investors on Wednesday.

Shares of Asterias Biotherapeutics (AST) opened at 3.30 on Wednesday. The firm’s 50-day moving average price is $3.49 and its 200-day moving average price is $3.50. The company’s market capitalization is $162.57 million. Asterias Biotherapeutics has a 12 month low of $2.54 and a 12 month high of $5.80.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/05/asterias-biotherapeutics-inc-ast-downgraded-by-valuengine.html.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.